PAVmed Q2 EPS $(1.19) Beats $(1.45) Estimate, Sales $979.00K Miss $1.20M Estimate
Portfolio Pulse from Benzinga Newsdesk
PAVmed (NASDAQ:PAVM) reported Q2 earnings per share (EPS) of $(1.19), beating the analyst estimate of $(1.45) by 17.93%. However, sales of $979K missed the $1.20M estimate by 18.42%. Despite the miss, sales increased by 489.76% year-over-year.
August 13, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PAVmed reported Q2 EPS of $(1.19), beating estimates by 17.93%, but sales of $979K missed the $1.20M estimate by 18.42%. Sales increased by 489.76% YoY.
The EPS beat is a positive indicator, showing better-than-expected cost management or revenue generation. However, the sales miss could temper investor enthusiasm. The significant YoY sales increase is a strong positive, suggesting growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100